Effects of Methylprednisolone on Immunological Function and Postoperative Pain

• Status: Completed
• Trial end date: 2017-01-15
• Target enrollment: 0
• Participant gender: All

Summary

Surgical trauma is characterized by a tightly integrated sequence of neurohumoral and immunological processes. When this is marked, it can manifest as a clinical entity called the systemic inflammatory response syndrome. Previous studies reported that inflammatory milieu in the postoperative period can be a harmful and potentially modifiable condition that may affect postoperative recovery, which includes the level of pain, fatigue, dizziness, nausea and vomiting (PONV), muscle weakness, and sleep quality and then increases the need for hospitalization. The effect of postoperative inflammation-related immune suppression such as the T-cell exhaustion and lymphocyte anergy may render the patient vulnerable to both infection and the recurrence of malignancy on postoperative infection risk and malignancy recurrence are currently subjects of intense speculation and investigation.

Glucocorticoids are well known for their analgesic, anti-inflammatory, immunosuppressive agents and antiemetic effects. Though previous studies' results on postoperative outcome have been positive and in favor of glucocorticoid use, with postoperative nausea and vomiting and pain outcome parameters most significantly improved. However, high-dose methylprednisolone treatment could result in decreases T-cells postoperatively. Based on these consideration, the aim of our study was to assess the effect of a single low-dose preoperative methylprednisolone (MP) 1 mg/Kg i.v. on postoperative pain and immune functions in patients undergoing video-assisted thoracoscopic surgery (VATS) under general anesthesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shengjing Hospital
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• ASA Ⅱ～Ⅲ

• aged 65-85years

• consciousness,with no psychological or communication disorders, with educational level above primary school (including primary school).

• with no chemotherapy or radiotherapy before admission.

• no history of medicine allergy.

• no evident abnormality of liver, kidney or nervous system

• scheduled for radical operation for lung cancer under general anesthesia

Exclusion Criteria:

• diagnosed with diseases in nervous system or psychological disorder, history of taking sedatives or anti-depressants.

• history of hypertension, diabetes, coronary heart disease, cerebral infarction.

• had drugs which affect immunological function before.

• severe acuity or vision dysfunction or have difficulty in communication.

• with special complications during surgery.

• had blood transfusion treatment during perioperation period history of heart operation

• Mini-mental State Examination Scores less than 25 before surgery.